Clinical Trials Browser

Completed × Neoplasms × Rituximab × Clear all

NCT01804712 2026-03-12

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

Phase EARLY_PHASE1 Completed

8 enrolled 12 charts

Neoplasms, Prostatic Neoplasms

NCT00006436 2025-12-30

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Phase 2 Completed

68 enrolled 24 charts

Acquired Immunodeficiency Syndrome, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Phase 1/2 Completed

53 enrolled 17 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Phase 1 Completed

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01788020 2024-05-13

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Phase 3 Completed

Waldenstrom Macroglobulinemia, Neoplasms

NCT01682616 2023-06-06

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase 1 Completed

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01594229 2021-08-02

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin, Neoplasms

NCT00983619 2020-05-13

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Phase 1/2 Completed

136 enrolled 56 charts

Neoplasms

NCT00500058 2017-07-26

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

Phase 1 Completed

Lymphoma, Non-Hodgkin, Neoplasms

NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Phase 2 Completed

20 enrolled 6 charts

Lymphoma, Neoplasms, Lymphoma, B-Cell

NCT01014208 2015-08-07

ORCHARRD

Phase 3 Completed

447 enrolled 21 charts

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00440388 2010-08-27

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Follicular, Neoplasms